|
1
|
Trotter SC, Sroa N, Winkelmann RR, Olencki
T and Bechtel M: A global review of melanoma follow-up guidelines.
J Clin Aesthet Dermatol. 6:18–26. 2013.PubMed/NCBI
|
|
2
|
Soengas MS and Lowe SW: Apoptosis and
melanoma chemoresistance. Oncogene. 22:3138–3151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wouters J, Stas M, Gremeaux L, Govaere O,
Van den Broeck A, Maes H, Agostinis P, Roskams T, van den Oord JJ
and Vankelecom H: The human melanoma side population displays
molecular and functional characteristics of enriched
chemoresistance and tumorigenesis. PLoS One. 8:e765502013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hersey P, Zhang XD and Mhaidat N:
Overcoming resistance to apoptosis in cancer therapy. Adv Exp Med
Biol. 615:105–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobori M, Yoshida M, Ohnishi-Kameyama M,
Takei T and Shinmoto H:
5alpha,8alpha-Epidioxy-22E-ergosta-6,9(11),22-trien-3beta-ol from
an edible mushroom suppresses growth of HL60 leukemia and HT29
colon adenocarcinoma cells. Biol Pharm Bull. 29:755–759. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen YK, Kuo YH, Chiang BH, Lo JM and
Sheen LY: Cytotoxic activities of 9,11-dehydroergosterol peroxide
and ergosterol peroxide from the fermentation mycelia of
Ganoderma lucidum cultivated in the medium containing
leguminous plants on Hep 3B cells. J Agric Food Chem. 57:5713–5719.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cui YJ, Guan SH, Feng LX, Song XY, Ma C,
Cheng CR, Wang WB, Wu WY, Yue QX, Liu X and Guo DA: Cytotoxicity of
9,11-dehydroergosterol peroxide isolated from Ganoderma
lucidum and its target-related proteins. Nat Prod Commun.
5:1183–1186. 2010.PubMed/NCBI
|
|
8
|
Parhira S, Zhu GY, Li T, Liu L, Bai LP and
Jiang ZH: Inhibition of IKK-β by epidioxysterols from the flowers
of Calotropis gigantea (Niu jiao gua). Chin Med. 11:92016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sliva D: Ganoderma lucidum (Reishi)
in cancer treatment. Integr Cancer Ther. 2:358–364. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng S and Sliva D: Ganoderma
lucidum for cancer treatment: We are close but still not there.
Integr Cancer Ther. 14:249–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng L, Si JY and Wong YS: Ergosterol
peroxide and 9,11-dehydroergosterol peroxide from Ling Zhi or
Reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.)
P. Karst. (Aphyllophoromycetideae)mycelia inhibit the growth of
human breast adenocarcinoma MCF-7 cells. Int J Med Mushroom.
11:249–257. 2009. View Article : Google Scholar
|
|
12
|
Costa MA, Pellerito L, Izzo V, Fiore T,
Pellerito C, Melis M, Musmeci MT and Barbieri G: Diorganotin(IV)
and triorganotin(IV) complexes of
meso-tetra(4-sulfonatophenyl)porphine induce apoptosis in A375
human melanoma cells. Cancer Lett. 238:284–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gill BS Navgeet and Kumar S: Ganoderma
lucidum targeting lung cancer signaling: A review. Tumour Biol.
39:10104283177074372017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia Q, Zhang H, Sun X, Zhao H, Wu L, Zhu
D, Yang G, Shao Y, Zhang X, Mao X, et al: comprehensive review of
the structure elucidation and biological activity of triterpenoids
from Ganoderma spp. Molecules. 19:17478–17535. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michels J, Johnson PW and Packham G:
Mcl-1. Int J Biochem Cell Biol. 37:267–271. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nijhawan D, Fang M, Traer E, Zhong Q, Gao
W, Du F and Wang X: Elimination of Mcl-1 is required for the
initiation of apoptosis following ultraviolet irradiation. Genes
Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Lv J, Cheng Y, Du J, Chen D, Li C
and Zhang J: Apoptosis induced by Ginkgo biloba (EGb761) in
melanoma cells is Mcl-1-dependent. PLoS One. 10:e01248122015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quinn BA, Dash R, Azab B, Sarkar S, Das
SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, et al:
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig
Drugs. 20:1397–1411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akgul C: Mcl-1 is a potential therapeutic
target in multiple types of cancer. Cell Mol Life Sci.
66:1326–1336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mukherjee N, Lu Y, Almeida A, Lambert K,
Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, et al:
Use of a MCL-1 inhibitor alone to de-bulk melanoma and in
combination to kill melanoma initiating cells. Oncotarget.
8:46801–46817. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Zhang XD, Thompson JF and Hersey P: Mcl-1, Bcl-XL and Stat3
expression are associated with progression of melanoma whereas
Bcl-2, AP-2 and MITF levels decrease during progression of
melanoma. Mod Pathol. 20:416–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thallinger C, Wolschek MF, Wacheck V,
Maierhofer H, Günsberg P, Polterauer P, Pehamberger H, Monia BP,
Selzer E, Wolff K and Jansen B: Mcl-1 antisense therapy
chemosensitizes human melanoma in a SCID mouse xenotransplantation
model. J Invest Dermatol. 120:1081–1086. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Wu Q, Bu M, Hu L, Du WW, Jiao C, Pan
H, Sdiri M, Wu N, Xie Y and Yang BB: Ergosterol peroxide activates
Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in
human hepatocellular carcinoma cells. Oncotarget. 7:33948–33959.
2016.PubMed/NCBI
|
|
24
|
Iida Y, Ciechanover A, Marzese DM, Hata K,
Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, et al:
Epigenetic regulation of KPC1 ubiquitin ligase affects the NF-κB
pathway in melanoma. Clin Cancer Res. 23:4831–4842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
